Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06524518
PHASE2

A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive

Sponsor: Xuanwu Hospital, Beijing

View on ClinicalTrials.gov

Summary

A prospective, multicenter clinical study designed to explore the efficacy of adaptive therapy based on MRD status in patients with stage II-III non-small cell lung cancer(NSCLC) after treatment. Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).

Official title: Xuanwu Hospital Capital Medical University

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

213

Start Date

2024-08

Completion Date

2029-12

Last Updated

2024-08-06

Healthy Volunteers

No

Conditions

Interventions

DRUG

Chemotherapy combined with immunization

MRD positive patients receive chemotherapy ± immune for 4 cycles before adaptive therapy

Locations (1)

Xuanwu Hospital

Beijing, Eijing, China